Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.

Davies MA, Moultrie H, Eley B, Rabie H, Van Cutsem G, Giddy J, Wood R, Technau K, Keiser O, Egger M, Boulle A; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration..

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):270-8. doi: 10.1097/QAI.0b013e3182060610.

2.

Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.

Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, Tsai WY, Abrams EJ.

Lancet Infect Dis. 2012 Jul;12(7):521-30. doi: 10.1016/S1473-3099(12)70051-8. Epub 2012 Mar 16.

3.

Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.

Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G.

AIDS. 2008 Oct 18;22(16):2117-25. doi: 10.1097/QAD.0b013e328310407e.

4.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
5.

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.

Shiau S, Kuhn L, Strehlau R, Martens L, McIlleron H, Meredith S, Wiesner L, Coovadia A, Abrams EJ, Arpadi SM.

BMC Pediatr. 2014 Feb 12;14:39. doi: 10.1186/1471-2431-14-39.

6.

Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.

Meyers TM, Yotebieng M, Kuhn L, Moultrie H.

Pediatr Infect Dis J. 2011 Nov;30(11):974-9. doi: 10.1097/INF.0b013e31822539f6.

7.

Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.

Lindsey JC, Hughes MD, Violari A, Eshleman SH, Abrams EJ, Bwakura-Dangarembizi M, Barlow-Mosha L, Kamthunzi P, Sambo PM, Cotton MF, Moultrie H, Khadse S, Schimana W, Bobat R, Zimmer B, Petzold E, Mofenson LM, Jean-Philippe P, Palumbo P; P1060 Study Team..

Pediatr Infect Dis J. 2014 Aug;33(8):846-54. doi: 10.1097/INF.0000000000000337.

8.

Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.

Coovadia A, Abrams EJ, Strehlau R, Shiau S, Pinillos F, Martens L, Patel F, Hunt G, Tsai WY, Kuhn L.

JAMA. 2015 Nov 3;314(17):1808-17. doi: 10.1001/jama.2015.13631.

9.

Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

Dlamini JN, Hu Z, Somaroo H, Highbarger HC, Follmann DA, Dewar RL, Pau AK.

Pharmacotherapy. 2011 Feb;31(2):158-63. doi: 10.1592/phco.31.2.158.

10.

Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.

Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, Dabis F, Davies MA, Hoffmann CJ, Oyaro P, Parkes-Ratanshi R, Reynolds SJ, Sikazwe I, Wools-Kaloustian K, Zannou DM, Wandeler G, Egger M; IeDEA southern Africa, east Africa, and west Africa..

Lancet HIV. 2015 Jul;2(7):e271-8. doi: 10.1016/S2352-3018(15)00087-9. Epub 2015 Jun 16.

11.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
12.

Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004772. doi: 10.1002/14651858.CD004772.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;(5):CD004772.

PMID:
22786492
13.

Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.

Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, Wood R, Hernán MA, Sterne JA, Egger M, Boulle A; IeDEA-SA collaboration..

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):428-37. doi: 10.1097/QAI.0b013e3182557785.

14.

Second-line antiretroviral therapy: long-term outcomes in South Africa.

Murphy RA, Sunpath H, Castilla C, Ebrahim S, Court R, Nguyen H, Kuritzkes DR, Marconi VC, Nachega JB.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):158-63.

15.

CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.

Fairlie L, Karalius B, Patel K, van Dyke RB, Hazra R, Hernán MA, Siberry GK, Seage GR 3rd, Agwu A, Wiznia A; Pediatric HIV AIDS Cohort Study (PHACS), The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)..

AIDS. 2015 Oct 23;29(16):2109-19. doi: 10.1097/QAD.0000000000000809.

16.

Outcomes after virologic failure of first-line ART in South Africa.

Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, Gordon M, Ross D, Ewusi AD, Matthews LT, Kuritzkes DR, Marconi VC; South Africa Resistance Cohort Study Team..

AIDS. 2010 Apr 24;24(7):1007-12. doi: 10.1097/QAD.0b013e3283333639.

17.

Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation.

Desmonde S, Eboua FT, Malateste K, Dicko F, Ekouévi DK, Ngbeché S, Koueta F, Sy HS, Renner L, Koumakpai SA, Leroy V; IeDEA Pediatric West African Working Group..

AIDS. 2015 Jul 31;29(12):1527-36. doi: 10.1097/QAD.0000000000000707.

PMID:
26244392
18.

Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.

Akanmu AS, Adeyemo T, Lesi F, Bello FO, Okwuegbuna K, Oloko K, Awolola A, Ogunsola FT, Okonkwo P, Kanki PJ.

Curr HIV Res. 2015;13(3):176-83.

PMID:
25986368
19.

Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.

Ciaranello AL, Doherty K, Penazzato M, Lindsey JC, Harrison L, Kelly K, Walensky RP, Essajee S, Losina E, Muhe L, Wools-Kaloustian K, Ayaya S, Weinstein MC, Palumbo P, Freedberg KA.

AIDS. 2015 Jun 19;29(10):1247-59. doi: 10.1097/QAD.0000000000000672.

20.

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.

Shearer K, Brennan AT, Maskew M, Long L, Berhanu R, Sanne I, Fox MP.

J Int AIDS Soc. 2014 Oct 22;17:19065. doi: 10.7448/IAS.17.1.19065. eCollection 2014 Oct 22.

Supplemental Content

Support Center